Verification of performance specifications of a molecular test: cystic fibrosis carrier testing using the Luminex liquid bead array
- PMID: 22208482
- DOI: 10.5858/arpa.2010-0536-OA
Verification of performance specifications of a molecular test: cystic fibrosis carrier testing using the Luminex liquid bead array
Abstract
Context: The number of clinical laboratories introducing various molecular tests to their existing test menu is continuously increasing. Prior to offering a US Food and Drug Administration-approved test, it is necessary that performance characteristics of the test, as claimed by the company, are verified before the assay is implemented in a clinical laboratory.
Objective: To provide an example of the verification of a specific qualitative in vitro diagnostic test: cystic fibrosis carrier testing using the Luminex liquid bead array (Luminex Molecular Diagnostics, Inc, Toronto, Ontario).
Design: The approach used by an individual laboratory for verification of a US Food and Drug Administration-approved assay is described.
Results: Specific verification data are provided to highlight the stepwise verification approach undertaken by a clinical diagnostic laboratory.
Conclusions: Protocols for verification of in vitro diagnostic assays may vary between laboratories. However, all laboratories must verify several specific performance specifications prior to implementation of such assays for clinical use. We provide an example of an approach used for verifying performance of an assay for cystic fibrosis carrier screening.
Similar articles
-
Verification of performance specifications for a US Food and Drug Administration-approved molecular microbiology test: Clostridium difficile cytotoxin B using the Becton, Dickinson and Company GeneOhm Cdiff assay.Arch Pathol Lab Med. 2012 Jan;136(1):20-5. doi: 10.5858/arpa.2011-0138-OA. Arch Pathol Lab Med. 2012. PMID: 22208483
-
Introduction to molecular cystic fibrosis testing.Clin Lab Sci. 2006 Winter;19(1):24-31. Clin Lab Sci. 2006. PMID: 16617555
-
Test verification and validation for molecular diagnostic assays.Arch Pathol Lab Med. 2012 Jan;136(1):11-3. doi: 10.5858/arpa.2011-0212-ED. Arch Pathol Lab Med. 2012. PMID: 22208481
-
Emerging issues in cystic fibrosis newborn screening.Curr Opin Pulm Med. 2010 Nov;16(6):584-90. doi: 10.1097/MCP.0b013e32833e9e27. Curr Opin Pulm Med. 2010. PMID: 20814308 Review.
-
Screening practices for mutations in the CFTR gene ABCC7.Hum Mutat. 2000;15(2):135-49. doi: 10.1002/(SICI)1098-1004(200002)15:2<135::AID-HUMU2>3.0.CO;2-H. Hum Mutat. 2000. PMID: 10649490 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical